Salarius Pharmaceuticals Inc (SLRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
SLRX Stock Price Chart Interactive Chart >
SLRX Price/Volume Stats
| Current price | $2.11 | 52-week high | $11.10 |
| Prev. close | $2.05 | 52-week low | $1.07 |
| Day low | $1.86 | Volume | 17,400 |
| Day high | $2.20 | Avg. volume | 183,081 |
| 50-day MA | $2.30 | Dividend yield | N/A |
| 200-day MA | $3.51 | Market Cap | 4.81M |
Salarius Pharmaceuticals Inc (SLRX) Company Bio
Salarius Pharmaceuticals Inc is a clinical-stage oncology company. The Company specializes in targeting the epigenetic causes of cancers and developing treatments for patients. Salarius Pharmaceuticals serves patients and customers in the State of Texas.
Latest SLRX News From Around the Web
Below are the latest news stories about SALARIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SLRX as an investment opportunity.
Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual MeetingHOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that two abstracts related to the company’s novel molecular glue SP-3164 have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19 at the Orange County Co |
Salarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone SymposiaHOUSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces that Justine Delgado, Ph.D., Research Manager, will be presenting a poster titled “Pre-clinical Investigation of the LSD1 Inhibitor, SP-2577 (seclidemstat) in Small Cell Lung Cancer” at the Keystone Symposia o |
Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of TexasHOUSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the receipt of a $1.48 million payment under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT). The payment is part of a non-dilutive grant of approximately $16.1 million awarded to Salarius to support i |
Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development SummitPreclinical data show synergistic activity for the targeted protein degrader SP-3164 with rituximab in non-Hodgkin’s lymphomas, and significantly better performance than standard-of-care treatment Company plans to submit an Investigational New Drug application to the U.S. Food and Drug Administration and begin a Phase 1 trial in 2023 HOUSTON, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and pr |
Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development SummitDr. Aundrietta Duncan to discuss mechanism of action and SP-3164 activity in cancer models Company planning to submit an Investigational New Drug application to the U.S. Food and Drug Administration and begin a Phase 1 trial in 2023 HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces |
SLRX Price Returns
| 1-mo | -4.52% |
| 3-mo | 75.83% |
| 6-mo | -55.11% |
| 1-year | -79.21% |
| 3-year | -85.07% |
| 5-year | -99.95% |
| YTD | 37.91% |
| 2022 | -87.65% |
| 2021 | -45.54% |
| 2020 | -75.93% |
| 2019 | -54.18% |
| 2018 | -90.54% |
Loading social stream, please wait...